The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Chemotherapy involves using drugs to destroy cancer cells — either by killing them directly or stopping them from multiplying. For bladder cancer, chemotherapy is either intravesical (put ...

Patients with advanced bladder cancer that has spread to other parts of the body (metastasized) have responded well in a phase I clinical trial of an investigational drug, TYRA-300.

Here’s a summary of what happened last month. Medscape Medical News, November 05, 2024 Gilead Withdraws Bladder Cancer Drug in US After Failed Trial Gilead Sciences said on Friday it was ...

Bladder cancer is the second most common urologic cancer in men in the U.S., with high recurrence rates, especially in non-muscle-invasive cases. The FDA has accepted a new drug application for the ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

Gilead will no longer sell its combination drug Trodelvy to treat bladder cancer, announcing Friday it had agreed with the Food and Drug Administration to withdraw it following negative trial results.

Barcelona, Spain: Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a phase I clinical trial of an investigational drug ...